Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Other Non-Current Liabilities (2021 - 2025)

Foghorn Therapeutics (FHTX) has 3 years of Other Non-Current Liabilities data on record, last reported at $556000.0 in Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities changed N/A year-over-year to $556000.0; the TTM value through Dec 2025 reached $556000.0, changed N/A, while the annual FY2025 figure was $556000.0, N/A changed from the prior year.
  • Other Non-Current Liabilities reached $556000.0 in Q4 2025 per FHTX's latest filing, down from $656000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $856000.0 in Q1 2025 and bottomed at $29000.0 in Q4 2022.
  • Average Other Non-Current Liabilities over 3 years is $343000.0, with a median of $157000.0 recorded in 2021.
  • The widest YoY moves for Other Non-Current Liabilities: up 66.08% in 2022, down 79.72% in 2022.
  • A 3-year view of Other Non-Current Liabilities shows it stood at $143000.0 in 2021, then plummeted by 79.72% to $29000.0 in 2022, then skyrocketed by 1817.24% to $556000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $556000.0 in Q4 2025, $656000.0 in Q3 2025, and $757000.0 in Q2 2025.